US 12,295,929 B2
Intravenous baclofen formulations and treatment methods
James C. Cloyd, Minneapolis, MN (US); Adolfo L. Gomez, Sticklerville, NJ (US); Linda Krach, Minneapolis, MN (US); Robert L. Kriel, Minneapolis, MN (US); John Schrogie, Lansdale, PA (US); Stephen John Tucker, Chester, PA (US); and Rob Tuohy, Philadelphia, PA (US)
Assigned to ALLAYSIS, LLC, Weston, FL (US); and REGENTS OF THE UNIVERSITY OF MINNESOTA, Minneapolis, MN (US)
Filed by Allaysis, LLC, Weston, FL (US); and Regents of the University of Minnesota, Minneapolis, MN (US)
Filed on Apr. 19, 2023, as Appl. No. 18/136,777.
Application 17/164,366 is a division of application No. 16/458,994, filed on Jul. 1, 2019, granted, now 10,933,042, issued on Mar. 2, 2021.
Application 16/458,994 is a division of application No. 14/997,135, filed on Jan. 15, 2016, granted, now 10,350,183, issued on Jul. 16, 2019.
Application 18/136,777 is a continuation of application No. 17/164,366, filed on Feb. 1, 2021, abandoned.
Claims priority of provisional application 62/103,902, filed on Jan. 15, 2015.
Prior Publication US 2023/0248679 A1, Aug. 10, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/197 (2006.01); A61K 9/00 (2006.01); A61K 45/06 (2006.01); A61P 25/14 (2006.01)
CPC A61K 31/197 (2013.01) [A61K 9/0019 (2013.01); A61K 45/06 (2013.01); A61P 25/14 (2018.01)] 12 Claims
 
1. A method of treating or preventing baclofen withdrawal in a human subject presently being treated with a therapeutically effective amount of oral baclofen, the method comprising:
discontinuing oral administration of the therapeutically effective amount of baclofen to the subject;
administering to the subject a bolus intravenous dose of solution comprising about 75% of the therapeutically effective amount of oral baclofen; and
repeating administration of the bolus intravenous dose of baclofen about every 6 to 8 hours.